Award to be presented November 12, 2014 highlights lifelong personalized medicine vision
WASHINGTON (September 16, 2014)—
The Personalized Medicine Coalition (PMC) today announced that Mr. Mark Levin, co-founder of and partner at Third Rock Ventures, will receive the 2014 Leadership in Personalized Medicine Award for his long commitment to personalized medicine.
"I have always felt that the successful implementation of the principles of personalized medicine into medical practice will depend on the embrace of these principles in the business community," stated Raju Kucherlapati, Ph.D., Paul C. Cabot professor in the Harvard Medical School Department of Genetics and member of the Presidential Commission for the Study of Bioethical Issues, who nominated Levin for this year's recognition. His letter stated that no one better exemplifies that commitment than Levin. "Mark relentlessly pursues perfection, and is daring to bring forth novel ideas that can change the world... This is what leadership is all about."
Mark Levin is a co-founder of Third Rock Ventures and an industry leader with 40 years of experience, most of which were spent launching and building biotechnology companies, including many focused on personalized medicine. At Third Rock Ventures, Levin runs the discovery process to conceive and launch companies around disruptive technologies and innovative science that promise to dramatically improve patients' lives.
Brian Munroe, PMC board member and senior vice president of government affairs at Endo Health Solutions, seconded the nomination, noting that Levin founded PMC "in the belief that personalized medicine has the potential to revolutionize pharma and biotech," but that personalized medicine "faces challenges in funding, regulation and implementation, and that the only way the field can reach its potential is if all the stakeholders band together."
Prior to Third Rock, Mark was co-founder of Mayfield Fund's life sciences effort, where he was also the founding CEO of Tularik, Cell Genesys/Abgenix, Focal, Stem Cells and Millennium Pharmaceuticals. He served as CEO of Millennium Pharmaceuticals for 12 years. Earlier in his career, he was an engineer and project leader at Lilly and Genentech. He holds an M.S. in chemical and biochemical engineering from Washington University.
"Thank you for this wonderful honor," stated Mr. Levin. "The best part of the last 40 years has been working with incredible people... to make a difference for patients. It cannot get any better than that!"
Previous recipients of the award include Dr. Janet Woodcock, director of the Food and Drug Administration's Center for Drug Evaluation and Research, Dr. Elizabeth G. Nabel, director of the National Heart, Lung and Blood Institute at the National Institutes of Health, Dr. Ralph Snyderman, chancellor emeritus of Duke University, Health and Human Services Secretary Michael Levitt, Brook Byers of Kleiner Perkins Caufield & Byers, Dr. William Dalton, president and CEO of the Moffitt Cancer Center, Dr. Leroy Hood, president and co-founder of the Institute for Systems Biology, Randal W. Scott, Ph.D., founder, Genomic Health Inc. and current chairman and CEO, InVitae Corporation, and Kathy Giusti, founder and CEO of the Multiple Myeloma Research Foundation.
Mr. Levin will be honored at the PMC Boston Cocktail Reception the evening of November 11 at the Hotel Commonwealth in Boston, Mass., and the award will be presented at the Personalized Medicine Conference, which will be held at Harvard Medical School on November 12, 2014, and at which Mr. Levin will deliver an address on his vision of personalized medicine. The Personalized Medicine Conference is co-hosted and presented by Partners HealthCare Center for Personalized Genetic Medicine (PCPGM), Harvard Business School and Harvard Medical School. The Conference is organized by PCPGM in association with the American Association for Cancer Research and PMC. The distinctive collaboration of this group of organizations reflects the diversity, depth and breadth of the Conference's program.
About the Personalized Medicine Coalition:
The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, visit www.personalizedmedicinecoalition.org.